騰盛博藥(02137.HK)「BRII-296」年內開展二期臨床試驗
騰盛博藥(02137.HK)公布,正在開發用於治療產後抑鬱症(PPD)的長效單次注射療法「BRII-296」一期研究公布頂線結果,研究數據表明單次肌內注射600mg的BRII-296實現線性劑量、早期藥物吸收、逐漸和延長釋放曲線,而無需劑量滴定或逐漸減少,為在該劑量下實現PPD治療的臨床療效打下堅實基礎。
公司中樞神經系統疾病治療領域主管Aleksandar Skuban表示,本研究的初步結果向前邁進重要一步,將在今年晚些時間繼續推進BRII296的二期研究,選定的劑量方案將在預計的二期臨床試驗中進行評估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.